Volume 28, Number 9—September 2022
CME ACTIVITY - Research
Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019
Table 3
Clinical syndromes of invasive group A Streptococcus disease, overall and by 6-year periods, Idaho, USA, 2008–2019*
Type of infection or clinical syndrome | No. (%) patients |
p value‡ | ||
---|---|---|---|---|
Overall, N = 476† | 2008–2013, n = 82† | 2014–2019, n = 394 | ||
Bacteremia without focus§ | 163 (34.2) | 34 (41.5) | 129 (32.7) | 0.13 |
Cellulitis | 197 (41.4) | 30 (36.6) | 167 (42.4) | 0.33 |
Pneumonia | 80 (16.8) | 15 (18.3) | 65 (16.5) | 0.69 |
Streptococcal toxic shock syndrome | 25 (5.3) | 0 (0.0) | 25 (6.4) | 0.02 |
Septic arthritis | 24 (5.0) | 6 (7.3) | 18 (4.6) | 0.30 |
Empyema | 19 (4.0) | 4 (4.9) | 15 (3.8) | 0.65 |
Necrotizing fasciitis | 12 (2.5) | 4 (4.9) | 8 (2.0) | 0.14 |
Osteomyelitis | 6 (1.3) | 0 (0.0) | 6 (1.5) | 0.26 |
Meningitis | 4 (0.8) | 0 (0.0) | 4 (1.0) | 0.36 |
Other¶ | 3 (0.6) | 1 (1.2) | 2 (0.5) | 0.46 |
*Cases can have >1 type of infection or clinical syndrome. †Excludes 7 cases with missing data on type of infection or clinical syndrome, all during 2008–2013. ‡By χ2 test. §Group A Streptococcus isolated from blood, with no other clinical syndrome identified. ¶Other includes abscess, epiglottitis, and pelvic inflammatory disease.